how to buy biio stock

Is biio stock going to be listed on NASDAQ?

May 03, 2022 · Bionovate Technologies Corp Stock Forecast. BUY SELL PINK: BIIO. $0.0800 (0%) Volume: 0. Closed: Apr 29, 2022. Watchlist. Report. Split - Wrong Prices/Values Doesn't exist …

Which way will biio go?

BIIO | Complete Bionovate Technologies Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. ... buy back about $10 bln of stock 7:03a ...

How do I buy stocks?

Find the latest Bionovate Technologies Corp (BIIO) stock quote, history, news and other vital information to help you with your stock trading and investing.

Is an online brokerage account a good way to buy stocks?

BIIO Stock Price Chart Interactive Chart > BIIO Price/Volume Stats. Current price $0.00 : 52-week high $10.25 : Prev. close ... • 3 Must-Own Dow Jones Stocks to Buy in May View All Top …

Is Bionovate a good stock to buy?

What does BIIO company do?

Is biotechnology innovation organization a non profit?

Is Baudax bio a buy?

What is Bionovate 20 F?

In connection with its application to list on NASDAQ, Bionovate will file a Form 20-F Registration Statement with the United States Securities and Exchange Commission (SEC).

What is fair value in accounting?

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Who is the CEO of Bionovate Technologies?

27, 2020 (GLOBE NEWSWIRE) -- The medical device company Bionovate Technologies Corp adopts a strategic reorientation under new management. Aleksandar Vucak will realign the company as CEO after taking over the majority of the shares of the company, traded on the Nasdaq OTC (OTCPK:BIIO). Bionovate Technologies Corp. will focus on investments and the marketing of patents and licenses which bring healthcare and lifestyle diagnostics to the smartphone. With strong emphasis on digital transformation, the company intends to build an FDA-approved ecosystem of medical devices, biosensors and mobile applications to turn tests that were previously only done in physical labs into tests that can be carried through by anyone with a mobile device. Innovations in these fields are transforming some of the most promising, high-growth-opportunity segments in the medical device market worldwide. To this end, new products and services will be developed in the coming months on the basis of existing patents. The focus will be on the acquisition of medical data from non-invasive sources (e.g. ultrasound, impedance measurements, motion profiles, other visualisation procedures) and their direct connection to mighty Big Data platforms, which use machine learning and artificial intelligence to provide the data as simple and clear as possible for the end user. With these new methods of wearable biosensing, which go far beyond the signals recorded so far, health-conscious and sporty consumers can measure and implement their fitness and health goals much better. CEO Aleksandar Vucak: "A wide range of applications and digital services in the lifestyle and medical care sectors are possible here. The entire wearables market is facing major disruptions because much more wearable biosensing is finally becoming possible. Completely new methods of signal processing and innovative digital communication architectures. We are just crossing the threshold from ‘Quantify Yourself’ to ‘Know Yourself’. In this wave of innovation that is about to hit the market, we want to make a contribution to ensuring that many people live more health-consciously, listen to their body's warning signals early on and thus live better."Bionovate Technologies Corp. Gewerbestr. 10 6330 Cham SwitzerlandPress contact: Sandra Meyer Tel: +41 581 01 02 02 Mail: [email protected]

Is Bionovate listed on the NASDAQ?

CHAM, Switzerland, May 03, 2021 (GLOBE NEWSWIRE) -- Bionovate Technologies Corp., traded on OTC Markets (OTCPK:BIIO), announced that it has submitted a formal application to list its common shares (“Shares”) on the NASDAQ Stock Exchange (“NASDAQ”). NASDAQ is the second largest exchange by market capitalization worldwide and is home to many of the world’s best technology companies. In connection with its application to list on NASDAQ, Bionovate will file a Form 20-F Registration Statement with the United States Securities and Exchange Commission (SEC). Acceptance for listing the Company’s shares is subject to approval based on several factors including satisfaction of minimum listing requirements for the NASDAQ Capital Market. The Company intends to satisfy all the applicable listing requirements. With the listing Bionovate is entering an important phase into a fast growing medical device market worldwide. About Bionovate Technologies Corp.Bionovate Technologies Corp. focuses on investments and the marketing of patents and licenses which bring healthcare and lifestyle diagnostics to your smartphone. With strong emphasis on digital transformation, the company intends to build an ecosystem of medical devices and mobile applications to turn health care data into personal digital services with a great user experience on mobile devices. Innovations in this field are transforming some of the most promising, high-growth-opportunity segments in the medical device market worldwide. Safe Harbor StatementThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control. Bionovate Technologies Corp.Gewerbestr. 106330 ChamSwitzerland Press contact:Sandra MeyerTel: +41 581 01 02 02Mail: [email protected]

Component Grades

We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.

Bionovate Technologies Corp. (BIIO) Company Bio

Bionovate Technologies Corp. manufactures lighting fixtures. The Company produces and markets light-emitting diode lighting products. Bionovate Technologies serves customers in North America and China.

What happens when you search for hot stocks?

When you’re searching for hot stocks, you can end up with a big list of stocks that offer some trading potential. It happens to everyone.

What is news catalyst?

News, rumors, social media mentions, and SEC filings are collectively called news catalysts.

What is the FDA approval process for biotech stocks?

In the United States, if a company wants to develop and sell a drug to the public, they need to pass stringent testing by the government’s Food and Drug Administration Agency (FDA).

What happens to stock after a phase?

After a company successfully passes a phase, its stock can spike in price. The good news can draw trader and investor interest in the company’s prospects for future profits. Of course, these spikes in price can and do often fail. So it’s critical to do thorough research and stick to your trading plan.

What is an OBLN?

OBLN is a tiny firm that focuses on developing medical devices to assist in weight loss for overweight and obese people. When I say tiny, I mean it — they currently have a market cap of just over $15 million.

What is the phase 1 of biotech?

If you’re going to trade biotechs, it’s always a good idea to know where the company’s drug (or drugs) is in the FDA approval process. Phase 1 (Safety Testing ): In this phase, the product is tested on 20–80 healthy individuals to determine whether the product is safe and the appropriate dosage.

How long does it take to get a placebo in Phase 3?

That means more safety testing, controls (certain patients will receive placebos), and strict product testing. This phase often takes two to three years.

What is Bionovate Technologies?

Founded in 2012, Bionovate Technologies is a medical device company. With a strong focus on digital transformation, Bionovate plans to develop an FDA-approved platform of medical devices, mobile apps, and biosensors to turn tests that were earlier only performed in physical laboratories into tests that anyone with a mobile device can perform.

How much is Biio's net loss for 2020?

In the three months ended December 2020, the company reported a net loss of $32,434 compared to $45,569 in the same period a year ago. Also, the company doesn’t generate any revenues. As of December 2020, BIIO had total liabilities of $451,973 and no cash flow.

Is Biio stock on the Nasdaq?

On May 3, BIIO stock surged significantly after the company said that it had filed an application to list its common stock on the Nasdaq Exchange. Nasdaq is the world’s second-largest exchange in terms of market capitalization and it's home to most of the best tech companies worldwide. BIIO stock is up 37 percent over the last month ...

Is Biio a penny stock?

BIIO is a penny stock and none of the Wall Street analysts have provided a forecast for the healthcare company. We also don’t have any reliable earnings estimates for the company. Currently, BIIO has 45.6 million outstanding shares.

What is equity summary score?

The Equity Summary Score is an accuracy-weighted sentiment derived from the ratings of independent research providers on Fidelity.com. It uses the past relative accuracy of the providers in determining the emphasis placed on any individual opinion. Learn More....

What is Bionovate technology?

Bionovate Technologies Corp., a medical device company, focuses on developing automated treatment for age spots. It intends to develop and provide automated computerized system that treats age spots anywhere on the body. The company targets to sell its systems to physicians and spas worldwide.

Where is Bionovate located?

and changed its name to Bionovate Technologies Corp. in December 2017. Bionovate Technologies Corp. was founded in 2010 and is based in Cham, Switzerland.

Is the stock market volatile?

Yield and return will vary, therefore, you may have a gain or loss when you sell your shares. Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments.

What is the difference between a biotech and a biotech?

In addition, a biotech with more experimental drugs in its pipeline (the term used to refer to all a company’s drugs that are in development) will tend to have less risk than a biotech with only one or a very few drug candidates. Another important thing to watch with biotechs is their financial positions.

What is Axsome 05?

Axsome Therapeutics. Axsome's lead candidate drug, which it calls AXS-05, targets depression and Alzheimer’s disease-related agitation. In early 2021, the company formally filed for U.S. regulatory approval for the drug to treat depression. It’s also evaluating AXS-05 in a phase 2 study for smoking cessation.

What are the opportunities for biotech companies?

The COVID-19 pandemic has also created massive opportunities for biotechnology companies that are developing treatments and vaccines for the virus.

How much is AXS 05 worth?

If approved, AXS-05 as a depression treatment could be a blockbuster drug, with peak annual sales -- the highest dollar-volume of sales per year analysts project -- estimated at $2.6 billion.

What is biotech company?

What exactly is a biotech? It’s a company that uses living organisms (for example, bacteria or enzymes) to make drugs. This use of living organisms differentiates biotechs from pharmaceutical companies, which use chemicals to develop drugs.

How many steps are there in biotech?

Drugs in later phases are more likely to succeed, making investing in that company less risky. There are four major steps and three phases that biotech companies follow to develop new drugs:

Who makes Regeneron eye medicine?

The biggest moneymaker for Regeneron is Eylea, an eye disease drug that Regeneron makes in collaboration with biopharma company Bayer (OTC:BAYRY). All net sales from Eylea in the U.S. are awarded to Regeneron, and the company splits with Bayer the revenue earned from markets outside of the U.S.

How does dollar cost averaging work?

Dollar-cost averaging provides a solution to this problem: Buy stocks with a set amount of money at regular intervals, and you may pay less per share on average over time. Crucially, dollar-cost averaging allows you to get started buying stocks right away, with a little bit of money, rather than waiting to build your balance. This mitigates the risk you buy either extremely high or low since you’re spreading out your purchases across a long period of time.

What is the best way to buy stocks?

An online brokerage account is the most convenient place to buy stocks, but it’s far from your only option. If you see yourself as a hands-on investor who likes researching companies and learning about markets, an online brokerage account is a great place to get started buying stocks.

What is dividend stock?

Dividend stocks pay out some of their earnings to shareholders in the form of dividends. When you buy dividend stocks, the goal is to achieve a steady stream of income from your investments, whether the prices of your stocks goes up or down. Certain sectors, including utilities and telecommunications, are also more likely to pay dividends.

What is value investing?

Value stocks are shares of stock that are priced at a discount and stand to see price gains as the market comes to recognize their true value. With value investing, you’re looking for “shares on sale,” with low price-to-earnings and price-to-book ratios. The aim is to buy stocks that are underpriced and hold on to them over the long term.

What is a robo advisor?

Robo-advisors are automated investing platforms that evaluate your financial goals, investing timeline and risk tolerance. When you sign up for a robo-investor, the platform asks you a series of questions to evaluate these factors and then invests your money in a managed portfolio of exchange traded funds (ETF) that’s tailored to your needs.

What is an IRA account?

If you want to buy stocks to fund your retirement, consider an individual retirement account (IRA) that offers you certain tax advantages, like tax-deferred growth of your investments and potential tax credits on your tax return.

What is growth stock?

Growth stocks are shares of companies that are seeing rapid, robust gains in profits or revenue. They tend to be relatively young companies with plenty of room to grow, or companies that are serving markets with lots of room for growth. Whether the shares of a growth stock seem expensive or not, investing in growth stocks assumes that continued rapid growth will deliver strong price gains over time.

What is discount broker?

Online/discount brokers are basically just order-takers and provide the least expensive way to start investing since there is typically no office to visit and no certified financial planners or advisors to assist you. The only interaction with an online broker is over the phone or via the Internet.

What is a robo advisor?

Roboadvisors are digital asset managers that cater to those who want to just set-it-and-forget-it. These algorithmic platforms are low-cost, require low minimum balances and will automatically maintain an optimal portfolio for you, typically based on passive index investing strategies. For instance the typical fee for roboadvisors is currently around 0.25% per year of assets under management, and you can start with literally $1 or $5 with several platforms. 3 

What are the different types of stockbrokers?

There are four basic categories of stockbrokers available today, ranging from cheap, simple order-takers to the more expensive brokers who provide full-service, in-depth financial analysis, advice, and recommendations: online/discount brokers, discount brokers with assistance, full-service brokers or money managers.

What is a full service broker?

Full-service brokers are the traditional stockbrokers who take the time to sit down with you and know you both personally and financially. They look at factors such as marital status, lifestyle, personality, risk tolerance, age (time horizon), income, assets, debts and more.

How does an online broker work?

The only interaction with an online broker is over the phone or via the Internet. Cost is usually based on a per-transaction or per-share basis, allowing you to open an account with relatively little money. An account with an online broker allows you to buy and sell stocks/options instantly with just a few clicks.

What to do if you can't handle volatility?

If you can't handle the volatility, you need to create a new strategy – or consider hiring an ad visor. Working with one, even temporarily, is a way to get a crash education in investing. The key is to gain the knowledge to be able to make informed decisions and never blindly to follow the next stock tip you see.

What is money manager?

Money managers are basically for those with substantial incomes who would rather pay someone to fully manage their investments while they're doing the jobs that make the money. Minimum account holdings can range from $100,000 to $250,000 or more and may charge upwards of 1% a year of assets under management.